lifitegrast · Bausch And Lomb Inc · NDA 208073
Xiidra
Earliest generic entry, as listed
18 Dec 2033
Blocked by patent: US 11058677.
Listed patents · 9 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11058677 | drug product · sets the listed date | 18 Dec 2033 |
| US 9085553 | drug product | 25 Jul 2033 |
| US 8927574 | drug product | 12 Nov 2030 |
| US 9353088 | drug product | 21 Oct 2030 |
| US 9890141 | drug substance | 21 Oct 2030 |
| US 7314938 | drug substance, drug product | 25 Jun 2029 |
| US 8168655 | use U-1880 | 9 May 2029 |
| US 8367701 | drug product, use U-1880 | 15 Apr 2029 |
| US 9447077 | use U-1900 | 15 Apr 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208073 · 001 · RLD | solution/drops, ophthalmic | 5% | 18 Dec 2033 |
Expired or delisted (2)
- US 8084047 · substance, product · 17 May 2026
- US 8592450 · use U-1880 · 17 May 2026